Caffeine consumption and risk of dyskinesia in CALM-PD
| Autor: | Wills, Anne-Marie A, Eberly, Shirley, Tennis, Marsha, Lang, Anthony E, Messing, Susan, Togasaki, Daniel, Tanner, Caroline M, Kamp, Cornelia, Chen, Jiang-Fan, Oakes, David, McDermott, Michael P, Schwarzschild, Michael A, Parkinson Study Group |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Risk
Male Aging Clinical Sciences Parkinson Study Group Kaplan-Meier Estimate Neurodegenerative Levodopa Antiparkinson Agents Cohort Studies Dose-Response Relationship Pramipexole Double-Blind Method Clinical Research Caffeine Humans Benzothiazoles Proportional Hazards Models Retrospective Studies Aged Parkinson's Disease Neurology & Neurosurgery Dyskinesia Prevention Neurosciences Parkinson Disease Human Movement and Sports Sciences Middle Aged Adenosine A2 Receptor Antagonists Brain Disorders Drug-Induced Neurological Female Drug |
| Zdroj: | Movement disorders : official journal of the Movement Disorder Society, vol 28, iss 3 |
| Popis: | BackgroundAdenosine A2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia.MethodsWe examined the association between self-reported intake of the A2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson's severity, site, and initial treatment with pramipexole or levodopa.ResultsFor subjects who consumed >12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% CI, 0.37-1.01) compared with subjects who consumed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|